New Options for Achieving Glycemic Targets in T1 Diabetes: SGLT Inhibition
This interactive web activity provides an update on the efficacy of sodium-glucose co-transporter (SGLT) inhibitors for the treatment of patients with type 1 diabetes. The activity reviews clinical trial data on efficacy including study design and impact on HbA1C, weight, total daily insulin dose, and “time in range” with continuous glucose monitoring. Please see the infographic section for additional materials including the mechanism of action for SGLT inhibitors.
This activity has been designed to meet the educational needs of endocrinologists and other healthcare professionals involved in the diagnosis, treatment, or management of patients with T1D.
Upon completion of this activity, participants will be better able to do the following:
- Describe currently available adjunctive options for glycemic control.
- Evaluate the clinical trial data on the safety, efficacy, and potential clinical use of new and emerging sodium-glucose cotransporter (SGLT) 1 and 2 inhibitors in patients with Type 1 diabetes.
John B. Buse, MD, PhD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:
Relationship Identified With:
|John B. Buse, MD, PhD|
Consultant/Advisor: Neurimmune AGGrant/Research Support: Novo Nordisk A/S, Sanofi, and vTv Therapeutics
Non-faculty: Sandy Breslow, Alison Kemp, Bernard M. Abrams, MD, Marilu Kelly, MSN, RN, CNE, Louis Settembrino, CHCP, and Christina M. Ohnsman, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier, and Catalyst Medical Education, LLC.
CME Credit (Physicians)
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CE CREDITS (NURSING)
This continuing nursing education activity, provided by Elsevier, awards 0.75 contact hour for nurses.
Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257 for 0.75 contact hour.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Catalyst Medical Education, LLC., and Sanofi US and Lexicon Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.75 AMA PRA Category 1 Credit(s)™
- 0.75 Nursing Contact Hours
- 0.75 Non-physician